PharmaBlock Sciences Nanjing Inc Class A (300725) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PharmaBlock Sciences Nanjing Inc Class A (300725) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥83.36 Million ≈ $12.20 Million USD) by net assets (CN¥7.15 Billion ≈ $1.05 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PharmaBlock Sciences Nanjing Inc Class A - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how PharmaBlock Sciences Nanjing Inc Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of PharmaBlock Sciences Nanjing Inc Class A for a breakdown of total debt and financial obligations.
PharmaBlock Sciences Nanjing Inc Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PharmaBlock Sciences Nanjing Inc Class A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sinocare Inc
SHE:300298
|
0.072x |
|
Olaplex Holdings Inc
NASDAQ:OLPX
|
0.037x |
|
Zhejiang Wanliyang Transmission Co Ltd
SHE:002434
|
0.065x |
|
Kennedy-Wilson Holdings Inc
NYSE:KW
|
-0.005x |
|
Bell AG
SW:BELL
|
0.170x |
|
American Axle & Manufacturing
NYSE:AXL
|
0.188x |
|
Dalata Hotel Group Plc
IR:DHG
|
0.022x |
|
Nan Pao Resins Chemical Co Ltd
TW:4766
|
0.059x |
Annual Cash Flow Conversion Efficiency for PharmaBlock Sciences Nanjing Inc Class A (2013–2024)
The table below shows the annual cash flow conversion efficiency of PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see 300725 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.99 Billion ≈ $437.17 Million |
CN¥302.82 Million ≈ $44.31 Million |
0.101x | +16.30% |
| 2023-12-31 | CN¥2.83 Billion ≈ $414.45 Million |
CN¥246.84 Million ≈ $36.12 Million |
0.087x | -6.08% |
| 2022-12-31 | CN¥2.66 Billion ≈ $388.90 Million |
CN¥246.61 Million ≈ $36.09 Million |
0.093x | +2.44% |
| 2021-12-31 | CN¥2.63 Billion ≈ $384.52 Million |
CN¥238.03 Million ≈ $34.83 Million |
0.091x | -36.79% |
| 2020-12-31 | CN¥1.89 Billion ≈ $277.26 Million |
CN¥271.51 Million ≈ $39.73 Million |
0.143x | -16.44% |
| 2019-12-31 | CN¥740.87 Million ≈ $108.41 Million |
CN¥127.04 Million ≈ $18.59 Million |
0.171x | -35.79% |
| 2018-12-31 | CN¥599.73 Million ≈ $87.76 Million |
CN¥160.16 Million ≈ $23.44 Million |
0.267x | +146.14% |
| 2017-12-31 | CN¥503.59 Million ≈ $73.69 Million |
CN¥54.64 Million ≈ $8.00 Million |
0.108x | +21.17% |
| 2016-12-31 | CN¥254.15 Million ≈ $37.19 Million |
CN¥22.76 Million ≈ $3.33 Million |
0.090x | -52.32% |
| 2015-12-31 | CN¥146.56 Million ≈ $21.45 Million |
CN¥27.52 Million ≈ $4.03 Million |
0.188x | +37.48% |
| 2014-12-31 | CN¥87.18 Million ≈ $12.76 Million |
CN¥11.91 Million ≈ $1.74 Million |
0.137x | -47.68% |
| 2013-12-31 | CN¥70.16 Million ≈ $10.27 Million |
CN¥18.32 Million ≈ $2.68 Million |
0.261x | -- |
About PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, DNA encoded library technology, and mega virtual lib… Read more